Research programme: nucleotide therapeutics - enGene

Drug Profile

Research programme: nucleotide therapeutics - enGene

Alternative Names: EG 10; EG-02; EG-12; GEMS™-Insulin

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator enGene
  • Developer enGene; Janssen Biotech
  • Class DNA; Nucleotides; Proteins; RNA
  • Mechanism of Action Glucagon receptor antagonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus; Inflammatory bowel diseases
  • Research Cancer; Chronic obstructive pulmonary disease; Coeliac disease; Cystitis

Most Recent Events

  • 10 May 2017 enGene plans a phase I/IIa trial for Inflammatory bowel disease in Canada (enGene pipeline, May 2017)
  • 14 Oct 2015 enGene and Janssen Biotech agree to develop and commercialise new therapeutics for Inflammatory bowel diseases
  • 18 Jan 2011 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top